Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine (Q56892691)

2

0 references

Shuguang Zuo

3

0 references

Minyi Zhao

4

0 references

Xiaobin Wang

5

0 references

Xicai Wang

6

0 references

Yan Chen

7

0 references

Zhiping Wu

8

0 references

Zhaojun Ren

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

9

0 references

language of work or name

English

0 references

publication date

5 August 2011

0 references

published in

Vaccine

0 references

volume

29

0 references

issue

34

0 references

page(s)

5802-11

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Mapping of the Sites Involved in Ligand Association and Dissociation at the Extracellular Domain of the Kinase Insert Domain-containing Receptor for Vascular Endothelial Growth Factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Cloning of linear DNAs in vivo by overexpressed T4 DNA ligase: construction of a T4 phage hoc gene display vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Phage T4 SOC and HOC display of biologically active, full-length proteins on the viral capsid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Phage display of intact domains at high copy number: a system based on SOC, the small outer capsid protein of bacteriophage T4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Inhibition of Lewis lung tumor growth and metastasis by Ehrlich ascites tumor growing in the same host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Bacteriophage T4 nanoparticle capsid surface SOC and HOC bipartite display with enhanced classical swine fever virus immunogenicity: a powerful immunological approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Regulatory T cells: the physiology of autoreactivity in dominant tolerance and "quality control" of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051

The central role of CD4(+) T cells in the antitumor immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.051